| Steady-state clinical pharmacokinetics of bupropion extended-release in youths. | |
| | |
MedLine Citation:
|
PMID: 17135996 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To examine in children and adolescents the 24-hour, steady-state clinical pharmacokinetics of an extended-release (XL) formulation of bupropion (Wellbutrin XL). METHOD: Subjects were six male and four female patients (ages 11.5-16.2 years) prescribed bupropion XL in morning daily doses of either 150 mg (n = 5) or 300 mg (n = 5) for at least 14 days. During an overnight hospitalization, subjects had serial blood draws every 1.5 to 3 hours from an intravenous port to measure plasma levels of bupropion and its metabolites. Pharmacokinetic variables were determined by noncompartmental analysis for bupropion and exponential analyses for metabolites. RESULTS: Bupropion and metabolites demonstrated linear pharmacokinetics. Bupropion's mean maximum concentration (Cmax) was lower (p = .021) and its mean time to Cmax longer (p = .057) in the current sample on bupropion XL relative to a previously studied sample of youths on bupropion sustained-release (Wellbutrin SR). Mean 24-hour area under the curve ratios of metabolites to bupropion ranged from 1.0 for erythrohydrobupropion to 16.4 for hydroxybupropion. CONCLUSIONS: Once-daily dosing is justified in youths prescribed bupropion XL. The active metabolite hydroxybupropion probably has key pharmacodynamic effects, given its higher and more sustained levels relative to the other metabolites or to bupropion. |
| | |
Authors:
|
W Burleson Daviss; James M Perel; Boris Birmaher; George R Rudolph; Imad Melhem; David A Axelson; David A Brent |
Related Documents
:
|
20635476 - Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. 7855966 - Recovery of erectile function by the oral administration of apomorphine. 16330296 - Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-lab... 16375216 - A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in heal... 9263536 - Protective effect of recombinant human leukemia inhibitory factor against thrombocytope... 17825616 - Efficacy and tolerability of indiplon in older adults with primary insomnia. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Journal of the American Academy of Child and Adolescent Psychiatry Volume: 45 ISSN: 0890-8567 ISO Abbreviation: J Am Acad Child Adolesc Psychiatry Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-11-30 Completed Date: 2006-12-28 Revised Date: 2008-04-03 |
Medline Journal Info:
|
Nlm Unique ID: 8704565 Medline TA: J Am Acad Child Adolesc Psychiatry Country: United States |
Other Details:
|
Languages: eng Pagination: 1503-9 Citation Subset: IM |
Affiliation:
|
Western Psychiatric Institute & Clinic, University of Pittsburgh, USA. davissw@uthscsa.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antidepressive Agents, Second-Generation / administration & dosage, pharmacokinetics*, therapeutic use* Attention Deficit Disorder with Hyperactivity / drug therapy* Bupropion / blood, pharmacokinetics*, therapeutic use* Child Cytochrome P-450 CYP3A / metabolism Cytochrome P-450 Enzyme System / metabolism Delayed-Action Preparations / administration & dosage, therapeutic use Depressive Disorder, Major / drug therapy* Female Humans Male |
| Grant Support | |
ID/Acronym/Agency:
|
K23 MH065375/MH/NIMH NIH HHS; K23 MH065375-03/MH/NIMH NIH HHS; M-01 RR00084/RR/NCRR NIH HHS; P30 MH066371/MH/NIMH NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents, Second-Generation; 0/Delayed-Action Preparations; 34841-39-9/Bupropion; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.14.1/Cytochrome P-450 2B6, human; EC 1.14.14.1/Cytochrome P-450 CYP3A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Family relational factors in pediatric depression and asthma: pathways of effect.
Next Document: Early father involvement moderates biobehavioral susceptibility to mental health problems in middle ...